{"name":"Mather's Pharm. Co., Ltd.","slug":"mather-s-pharm-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"MSP01-R","genericName":"MSP01-R","slug":"msp01-r","indication":"Type 2 diabetes","status":"phase_3"},{"name":"MSP01-T","genericName":"MSP01-T","slug":"msp01-t","indication":"Type 2 diabetes","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Laybon Tab.","genericName":"Laybon Tab.","slug":"laybon-tab","indication":"Other","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Layla Tab.","genericName":"Layla Tab.","slug":"layla-tab","indication":"Hypertension","status":"marketed"}]}],"pipeline":[{"name":"MSP01-R","genericName":"MSP01-R","slug":"msp01-r","phase":"phase_3","mechanism":"MSP01-R is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"Laybon Tab.","genericName":"Laybon Tab.","slug":"laybon-tab","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Layla Tab.","genericName":"Layla Tab.","slug":"layla-tab","phase":"marketed","mechanism":"Layla Tab is a combination of two medications, a calcium channel blocker and a beta blocker, which work together to lower blood pressure and reduce the workload on the heart.","indications":["Hypertension","Angina pectoris"],"catalyst":""},{"name":"MSP01-T","genericName":"MSP01-T","slug":"msp01-t","phase":"phase_3","mechanism":"MSP01-T is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxPMkhxZUY4bmViQS1RaTZ6Tld4cjFib1hOcjNEREFHdUp3akpRQUJtWjF4dHJhaUhfT0prQXcxYkVVdnU3SXVXdTJiUkdRdDRCdDFWdG10R0g5MXB4MlA4eXhPTHZiMXpKakVWTV9DMC1xajI5cmJqVTdiSGFiQnBiMEoyckc4MTYyZUVMS1Vna1NvRXRaN01RLUdFWUpZUkJhb2JHcWkzWVduQ3RXdTZZRUJEeGJOdVJ0RGM5cTRLdGNhRUtSTW0zeTRUaERCRkU?oc=5","date":"2026-04-04","type":"regulatory","source":"minichart.com.sg","summary":"Rhythm Pharmaceuticals Setmelanotide FDA Approval, Company Details, and XBRL Filing Information - minichart.com.sg","headline":"Rhythm Pharmaceuticals Setmelanotide FDA Approval, Company Details, and XBRL Filing Information","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxNY2g0UmVIOWFiYVhZa05yaS12Z1ZJTXp4TUprUlRsM0ZoTldUX25HSmh6dUZTS3B2MzNlc2FQY0k3LTRKZDJWN0l4cXlvVnVhZ3NueE1zcTlHbUFIUWc2MF9JMjV4bHRrNmxXNC1yUk93VHcwZ2dBX1pYTGxuaDlEWlUzQ1VSdXlSZXhtazBzVHFCR2RYT2FEQzhhN0dsNmZMNWJQZ2wycWk1WTQ?oc=5","date":"2026-04-03","type":"pipeline","source":"Stock Titan","summary":"Biotech veteran Kim Popovits joins Rhythm board as Ed Mathers leaves - Stock Titan","headline":"Biotech veteran Kim Popovits joins Rhythm board as Ed Mathers leaves","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxORElLWndOTFdsOTZvWXpHdFFUUTJ3Qmt3N1J4eGNGdE8xUnlZanJ6TVNZTzlTS2drZVJoSE9TV2lJQWFndjFGdXRFcXFxalZhNWwyNXlZWDFBYXc1bXc2YUpWcHVDb19hTEdQS1Z0YlYwV2x6VDV5ZGJsU3NRV2VYV1JLa0tMZ2MtRFQyUjBJMnFYRzJJOXJJ?oc=5","date":"2026-04-03","type":"pipeline","source":"citybiz","summary":"Rhythm Pharmaceuticals Appoints Kim Popovits to Board - citybiz","headline":"Rhythm Pharmaceuticals Appoints Kim Popovits to Board","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPSEE5MWsta3ZTcjBQUVRxQ2VPTHlzWWNfMWtpY0tzYlZTaVhvWWlha1ZoRXV6cnkwNEwxZTBvTFRwaXdscHdGYWZ5OGlfS2E4eEFOUGpuQk9mTXBmVDVxcHRFNWtmampSdk5jWlVjNHFvWi1RWmhuWmpjNER4U0ZUcHJsZFp5cmxfTXFJOTV2dmp0cFZYVDFPZmJqZHBMUDg1bDhacDFqSzhtYV9ldTNCb0cySElDUQ?oc=5","date":"2026-04-03","type":"pipeline","source":"Stock Titan","summary":"Kim Popovits joins Rhythm (NASDAQ: RYTM) board as Ed Mathers exits - Stock Titan","headline":"Kim Popovits joins Rhythm (NASDAQ: RYTM) board as Ed Mathers exits","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxORTlBcEtTRzNMM2NGSF9BbkQ4S0hMXzdtcDdJLU9zSVp6a3VuaVVDY0hHMEs4ZE04WndjOHB4QmhHUUthSk0wNTlvdk9TWHROenppeWY3LVdSaVFSaVluc283U0JFOW1WZThWSHk4MmNRY0RvWjl5T3ZfSHdlcUlCb1FoZGE2V05icDNibGVhVXpfc1BDeEVaRGZXY3FLeXRWZ1dBQ0ttN0N2OGU5M0V2emU3Zm5uTGstOWVGRQ?oc=5","date":"2026-03-16","type":"pipeline","source":"Stock Titan","summary":"Trust for Rhythm Pharmaceuticals (RYTM) director receives 4,199 shares - Stock Titan","headline":"Trust for Rhythm Pharmaceuticals (RYTM) director receives 4,199 shares","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAJBVV95cUxNQS1MeXBsS3NvTlVSUUphQ2YwUl9wTzU4X1RscTA1MjJjTmk0akw1VWRtYkh1a21seW1Ib1RCSTM0YXVJbmNoRUtTUWFTOXBXV0tDcW5OcExaMWlMQXhRZ0tCa0xhUGtPUE9MYXNvM1VSbzNjbWJ5WGZYdUFXSzJXR3VyZjV2bk45VWM2eVdQcjlwRmpTS0tQSUo0WDNtaTZydHhKZ0MtNmJwbWtLRWdObmJOcXFEZUYtVnpoeVlseTlOck9Gc0JJbE1QUnF6aFFFRTZNY2Mxc1pWZzJvVnNZTHpzQW9YejV1YWdDd0lkUW9sdlhFY240YVFHbDFBc1UyOE9UX1NBT3ItUzdVbTU3YlNUWkw3OU9Ld29TbnhiaUxKRUZzcXdselJPVzhlUU9PVktTMkZSWk1JaGNLMGxsV3kxTno?oc=5","date":"2026-03-01","type":"trial","source":"GlobeNewswire","summary":"Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity - GlobeNewswire","headline":"Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxNWTJpWmRxMFJDalpKN2VIRU4zbkxHeDFVbzNOQnlBWk1hQmZBS2hxOHhDOThtU1VPRV91bDBnMmVsWWc3ZGRZUkgxbVUxVXFwM2NaUURQM1BBaTU0dWt5cGZpcHpZVEg4VGN1QXEzWWlvM1VOelZxc29PNDIwTG5rOVdXR3F3aXBSWEZxeEE0MmFlTnFLMXA4T1pGNU0zb0FBMnJyTjlqUXpJaUJCa2pSSHlsODl5S2tmbjFXbFZkbGpTX28?oc=5","date":"2026-02-03","type":"pipeline","source":"Capital Brief","summary":"Telix Pharmaceuticals chair Tiffany Olson resigns - Capital Brief","headline":"Telix Pharmaceuticals chair Tiffany Olson resigns","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxQeDdHalYzSDUyQWUzRmE2bmZMZ1NHbVd2VldqYWw4V1lfVWVFZVg0VlhkWEViZTQxNUwzNno1eEZNOWNMYmluaEs3R3l3Nklrel9lZWM3ckJOUl96dHFQeGRUaWlZZHVPSzhaQTF4X3VFTlppbVpNWGQ1UGU4Vmx5ekVwaXV3ZXNJNmpGaFB5X3ZqZzBwNXZtU0tyLVIzNEVmUV9paVowSXZjNFBEYUZ0Vlp5NDRwcC05WkNaeGFzcHNWMF9mVjUyaVN6WDVOWkhI?oc=5","date":"2026-01-15","type":"pipeline","source":"Capital Brief","summary":"Cosette Pharmaceuticals to appeal Mayne Pharma court ruling - Capital Brief","headline":"Cosette Pharmaceuticals to appeal Mayne Pharma court ruling","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxQSEpYNmozQ3p1b1FnWGdmUWpDaWVMVU53QXREcHBHZEZKazZxR2tmdVI4ekp0TmliMjVDQWNJaGZaNVBnOEtYN3NoRzBBNnk0M25VbUFlNExXUzBramZqNXhXYUtQYzZKcTNUWXZrN29oS2VyeHdZXzQyLS1keDUxOHVDRURiX1BfNVBEa2NoMWk?oc=5","date":"2026-01-06","type":"deal","source":"The Business Journals","summary":"Sacramento pharmaceutical manufacturer Nivagen acquired by private equity-backed PAI Pharma - The Business Journals","headline":"Sacramento pharmaceutical manufacturer Nivagen acquired by private equity-backed PAI Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxNOTFMbFg2SjVIUGIyQkhxOTNXNTFib0FCU1JFRU9lSzlBRjRhQ1ZKZUxyZWtfUTBEWkVidnBiRU1aUEZaZG12Z25jWjFjVHhBUTVhZmVfRW5vV0VFcmE4UUhLRE1PWGo2Q0JUQTZtWVN3NE43dU5GcmE3a2RtS3lnNUd5OFR5R1BMVmFuZHkyWTF6c0thSVhBbVFoZ0wyUlhqeG1VUk91SDNzOVR6T1pwQkpXd0NvNTI0ZHctdlFyQS1qYVdjbHBubHEzNi02NXlZV1dYM2NXQ2YtR2s1UVpTdE03c1A0SVlwNW1GNGcyV0JmTE4xazg1Mmt3?oc=5","date":"2025-06-19","type":"regulatory","source":"Business Wire","summary":"Cycle Pharmaceuticals’ HARLIKU™ (nitisinone) Tablets Receive First FDA-Approval as Treatment for Alkaptonuria (AKU) - Business Wire","headline":"Cycle Pharmaceuticals’ HARLIKU™ (nitisinone) Tablets Receive First FDA-Approval as Treatment for Alkaptonuria (AKU)","sentiment":"positive"},{"url":"https://news.google.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?oc=5","date":"2025-05-06","type":"pipeline","source":"The Times of India","summary":"Driven by mother’s death, Karnataka Pharm D student becomes varsity topper - The Times of India","headline":"Driven by mother’s death, Karnataka Pharm D student becomes varsity topper","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNb3AtWE5KN3NZNjUzOU1xNzVrOTNRLS1oSWxnbkdteVlzckYxT2w0ajBvbUluSGFLOFVqc2haX0FaWXhHYTFRakFIbWgyTGtfUUdydzEwdFlpSnVuSjRHLUVKVk5Sdk85OVlpTWZ3cFM0dkVTaEtVaFNnYXNBR0Q2SXY0c05GS2VubXVYd1pKX28wd3JfWkdOY0ZueFhNeHVkSlcwQk1YUVNHb3M4bUpJZk1XOFdwRlBk?oc=5","date":"2020-03-24","type":"pipeline","source":"Holland & Knight","summary":"Section 101 Update: Pharmaceutical and Life Sciences March 2020 - Holland & Knight","headline":"Section 101 Update: Pharmaceutical and Life Sciences March 2020 - Holland & Knight","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_3":2,"marketed":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}